We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$36.5M
Cap. Flow
-$61.8M
Cap. Flow %
-8.41%
Top 10 Hldgs %
51.18%
Holding
61
New
18
Increased
7
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.1M
2
ICVX
Icosavax, Inc. Common Stock
ICVX
+$17.3M
3
MRSN
Mersana Therapeutics
MRSN
+$16.4M
4
ANNX icon
Annexon
ANNX
+$15.3M
5
CYTK icon
Cytokinetics
CYTK
+$14.8M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$38M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$37M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$24.8M
4
ASND icon
Ascendis Pharma A/S
ASND
+$16.1M
5
APLS
Apellis Pharmaceuticals
APLS
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
51
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$11K ﹤0.01%
66,666
– –
ALGS icon
52
Aligos Therapeutics
ALGS
$24.8M
– –
-40,000
Closed -$874K
ASND icon
53
Ascendis Pharma A/S
ASND
$16.7B
– –
-150,000
Closed -$16.1M
BHVN icon
54
Biohaven
BHVN
$2.2B
– –
-700,000
Closed -$9.56M
KYNB
55
Kyntra Bio
KYNB
$28.8M
– –
-12,000
Closed -$5.6M
IRON icon
56
Disc Medicine
IRON
$2.87B
– –
-525,000
Closed -$11.1M
MDGL icon
57
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-50,000
Closed -$12.1M
MLYS icon
58
Mineralys Therapeutics
MLYS
$2.46B
– –
-300,000
Closed -$4.7M
CBAY
59
DELISTED
Cymabay Therapeutics
CBAY
– –
-400,000
Closed -$3.49M
DICE
60
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-410,000
Closed -$11.7M
ISEE
61
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,520,000
Closed -$37M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2023 Portfolio in Review

As of Q2 2023, Logos Global Management held 61 positions worth $735M, up 5.2% from $699M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Logos Global Management withdrew a net $61.8M in Q2 2023, closing 10 positions and reducing 18 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Arcellx worth $15.8M.

  • Logos Global Management's largest Q2 2023 buy was Arcellx: 500,000 shares worth $15.8M.
  • Logos Global Management added most to Cytokinetics in Q2 2023, an estimated $14.8M increase.
  • Logos Global Management's biggest Q2 2023 reduction was IDEAYA Biosciences, cutting an estimated $38M.
  • Logos Global Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $37M.
  • Logos Global Management's ten largest holdings make up 51% of its $735M portfolio in Q2 2023.
  • Logos Global Management opened 18 new positions and closed 10 in Q2 2023.
  • Logos Global Management's portfolio value rose 5.2% quarter-over-quarter to $735M.

Based on Logos Global Management's 13F filing for Q2 2023, filed 14 Aug 2023.